Free Trial
→ Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel Free IKT Stock Alerts

Inhibikase Therapeutics (IKT) Financials

Inhibikase Therapeutics logo
$1.52 -0.01 (-0.65%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$1.52 -0.01 (-0.33%)
As of 11/13/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Inhibikase Therapeutics

Annual Income Statements for Inhibikase Therapeutics

This table shows Inhibikase Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -2.85 -15 -18 -19 -28 -48
Consolidated Net Income / (Loss)		 -2.85 -15 -18 -19 -28 -48
Net Income / (Loss) Continuing Operations		 -2.85 -15 -18 -19 -28 -48
Total Pre-Tax Income 		-2.85 -15 -18 -19 -28 -48
Total Operating Income		 -2.82 -15 -18 -20 -29 -52
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Operating Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 2.82 15 18 20 29 52
Selling, General & Admin Expense		 2.62 6.51 6.22 6.73 11 24
Research & Development Expense		 0.89 11 12 14 17 30
Other Operating Expenses / (Income)		 -0.70 -3.10 -0.12 -0.26 - -1.37
Total Other Income / (Expense), net		 -0.03 -0.02 0.07 1.06 1.03 3.72
Interest Expense		 0.03 0.02 -0.07 -1.06 -1.07 -3.72
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)		 - 0.00 -0.10 0.10 - -0.06
Basic Earnings per Share		 ($0.35) ($0.81) ($4.28) ($3.16) ($1.16) ($0.49)
Weighted Average Basic Shares Outstanding		 8.21M 18.21M 4.22M 6.03M 23.71M 98.31M
Diluted Earnings per Share		 ($0.35) ($0.81) ($4.28) ($3.16) ($1.16) ($0.49)
Weighted Average Diluted Shares Outstanding		 8.21M 18.21M 4.22M 6.03M 23.71M 98.31M
Weighted Average Basic & Diluted Shares Outstanding		 8.21M 18.21M 28.98M 6.48M 74.34M 132.03M

Quarterly Income Statements for Inhibikase Therapeutics

This table shows Inhibikase Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -4.65 -4.96 -5.78 -12 -14 -9.92 -12 -13 -16 -20 -20
Consolidated Net Income / (Loss)		 -4.65 -4.96 -5.78 -12 -14 -9.92 -12 -13 -16 -20 -20
Net Income / (Loss) Continuing Operations		 -4.65 -4.96 -5.78 -12 -14 -9.92 -12 -13 -16 -20 -20
Total Pre-Tax Income 		-4.65 -4.96 -5.78 -12 -14 -9.92 -12 -13 -16 -20 -20
Total Operating Income		 -4.78 -5.05 -5.83 -13 -15 -11 -13 -14 -18 -21 -22
Total Gross Profit		 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Operating Expenses		 4.78 5.05 5.83 13 15 11 13 14 18 21 22
Selling, General & Admin Expense		 2.03 1.97 1.64 5.74 5.25 5.92 5.61 6.77 7.38 7.66 7.23
Research & Development Expense		 2.75 3.08 4.19 7.19 11 5.27 7.65 6.36 11 13 15
Other Operating Expenses / (Income)		 0.00 0.00 0.00 - -1.16 -0.36 -0.49 0.64 -0.37 0.00 0.00
Total Other Income / (Expense), net		 0.13 0.09 0.05 0.80 0.92 0.91 0.84 1.00 1.46 1.46 1.76
Interest Expense		 -0.13 -0.09 -0.05 -0.80 -0.92 -0.92 -0.84 -1.04 -1.46 -1.46 -1.76
Basic Earnings per Share		 ($0.73) ($0.66) ($0.65) ($0.51) ($0.15) ($0.11) ($0.13) ($0.10) ($0.10) ($0.11) ($0.10)
Weighted Average Basic Shares Outstanding		 6.34M 7.54M 8.88M 23.71M 89.54M 90.01M 90.05M 98.31M 172.31M 174.57M 196.94M
Diluted Earnings per Share		 ($0.73) ($0.66) ($0.65) ($0.51) ($0.15) ($0.11) ($0.13) ($0.10) ($0.10) ($0.11) ($0.10)
Weighted Average Diluted Shares Outstanding		 6.34M 7.54M 8.88M 23.71M 89.54M 90.01M 90.05M 98.31M 172.31M 174.57M 196.94M
Weighted Average Basic & Diluted Shares Outstanding		 6.48M 7.46M 67.19M 74.34M 74.34M 74.52M 75.18M 132.03M 132.03M 139.54M 140.27M

Annual Cash Flow Statements for Inhibikase Therapeutics

This table details how cash moves in and out of Inhibikase Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 14 27 -34 1.98 47 83
Net Cash From Operating Activities		 -1.13 -14 -17 -18 -19 -28
Net Cash From Continuing Operating Activities		 -1.13 -14 -17 -18 -19 -28
Net Income / (Loss) Continuing Operations		 -2.85 -15 -18 -19 -28 -48
Consolidated Net Income / (Loss)		 -2.85 -15 -18 -19 -28 -48
Depreciation Expense		 - 0.00 0.01 0.18 0.03 0.06
Non-Cash Adjustments To Reconcile Net Income		 2.18 2.92 -0.45 1.54 8.40 20
Changes in Operating Assets and Liabilities, net		 -0.46 -2.43 1.14 -0.77 -0.05 0.50
Net Cash From Investing Activities		 0.00 0.00 -16 12 -37 2.05
Net Cash From Continuing Investing Activities		 0.00 0.00 -16 12 -37 2.05
Purchase of Property, Plant & Equipment		 - 0.00 -0.24 -0.01 0.00 -0.01
Acquisitions		 - - - - 0.00 -0.44
Purchase of Investments		 - 0.00 -21 -29 -60 -39
Sale and/or Maturity of Investments		 - 0.00 4.96 41 23 42
Net Cash From Financing Activities		 15 41 -0.20 8.41 103 108
Net Cash From Continuing Financing Activities		 15 41 -0.20 8.41 103 108
Issuance of Common Equity		 15 41 0.00 8.54 103 108
Other Financing Activities, net		 0.00 0.00 0.04 -0.14 0.00 0.85

Quarterly Cash Flow Statements for Inhibikase Therapeutics

This table details how cash moves in and out of Inhibikase Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents		 -6.81 0.73 -2.17 56 17 4.30 -39 101 -90 -18 20
Net Cash From Operating Activities		 -3.87 -5.05 -4.88 -5.35 -4.10 -5.57 -11 -7.52 -12 -12 -17
Net Cash From Continuing Operating Activities		 -3.87 -5.05 -4.88 -5.35 -4.10 -5.57 -11 -7.52 -12 -12 -17
Net Income / (Loss) Continuing Operations		 -4.65 -4.96 -5.78 -12 -14 -9.92 -12 -13 -16 -20 -20
Consolidated Net Income / (Loss)		 -4.65 -4.96 -5.78 -12 -14 -9.92 -12 -13 -16 -20 -20
Non-Cash Adjustments To Reconcile Net Income		 0.09 -0.04 0.37 7.97 9.46 5.35 2.92 3.38 5.23 1.99 0.86
Changes in Operating Assets and Liabilities, net		 0.68 -0.06 0.52 -1.19 0.10 -1.04 -1.60 1.84 -0.91 5.16 2.25
Net Cash From Investing Activities		 -3.31 2.54 2.53 -39 21 9.84 -29 -0.10 -80 -5.91 -13
Net Cash From Continuing Investing Activities		 -3.31 2.54 2.53 -39 21 9.84 -29 -0.10 -80 -5.91 -13
Purchase of Investments		 -8.43 -0.78 -1.13 -50 0.00 - -39 -0.10 -91 -55 -76
Sale and/or Maturity of Investments		 5.12 3.32 3.66 11 22 9.84 10 - 10 49 63
Net Cash From Financing Activities		 0.37 3.24 0.18 100 0.00 0.03 -0.13 109 2.90 -0.01 50
Net Cash From Continuing Financing Activities		 0.37 3.24 0.18 100 0.00 0.03 -0.13 109 2.90 -0.01 50
Repayment of Debt		 - - - - - - - - - - 0.01
Issuance of Common Equity		 0.40 3.21 0.18 100 0.00 0.00 - 108 2.90 - 49
Other Financing Activities, net		 -0.03 0.03 - - 0.00 0.03 -0.13 0.95 0.00 - 1.33

Annual Balance Sheets for Inhibikase Therapeutics

This table presents Inhibikase Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 15 42 25 15 99 181
Total Current Assets		 15 42 24 14 98 180
Cash & Equivalents		 14 41 7.19 9.17 56 139
Short-Term Investments		 - 0.00 16 4.09 41 40
Prepaid Expenses		 0.83 1.61 1.28 0.96 0.91 1.35
Other Current Assets		 - - - - - 0.00
Plant, Property, & Equipment, net		 0.00 0.00 0.24 0.07 0.05 0.00
Total Noncurrent Assets		 0.00 0.00 0.33 0.22 0.10 1.10
Other Noncurrent Operating Assets		 - 0.00 0.33 0.22 0.10 1.10
Total Liabilities & Shareholders' Equity		 15 42 25 15 99 181
Total Liabilities		 5.00 4.05 3.90 3.53 3.73 8.30
Total Current Liabilities		 4.72 4.05 3.70 3.44 3.73 8.30
Short-Term Debt		 0.04 0.00 0.15 0.15 0.11 0.00
Accounts Payable		 1.72 1.09 1.15 0.65 0.94 1.16
Accrued Expenses		 0.63 2.72 2.40 2.26 2.68 4.08
Other Current Liabilities		 - 0.25 0.00 0.38 0.00 3.06
Total Noncurrent Liabilities		 0.28 0.00 0.21 0.09 0.00 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 40 38 21 11 95 173
Total Preferred & Common Equity		 9.78 38 21 11 95 173
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 40 38 21 11 95 173
Common Stock		 25 68 69 78 189 316
Retained Earnings		 15 -30 -48 -67 -94 -143
Accumulated Other Comprehensive Income / (Loss)		 - 0.00 0.10 0.00 -0.04 0.02

Quarterly Balance Sheets for Inhibikase Therapeutics

This table presents Inhibikase Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets		 18 11 8.83 4.38 94 89 80 173 164 202
Total Current Assets		 18 11 8.60 4.19 94 89 79 172 162 199
Cash & Equivalents		 15 2.35 3.09 0.91 73 78 38 50 31 52
Short-Term Investments		 1.97 7.40 4.85 2.33 20 9.92 39 121 128 142
Prepaid Expenses		 0.72 1.06 0.66 0.39 0.98 0.82 0.83 1.81 3.28 5.41
Other Current Assets		 - - - 0.55 0.00 0.31 0.39 0.00 0.04 0.00
Plant, Property, & Equipment, net		 0.08 0.07 0.06 0.05 0.05 0.02 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 0.25 0.19 0.16 0.13 0.07 0.03 1.06 1.16 1.24 3.02
Other Noncurrent Operating Assets		 0.25 0.19 0.16 0.13 0.07 0.03 1.06 1.16 1.24 3.02
Total Liabilities & Shareholders' Equity		 18 11 8.83 4.38 94 89 80 173 164 202
Total Liabilities		 2.86 4.29 3.73 4.91 8.55 8.80 6.70 5.71 10 13
Total Current Liabilities		 2.74 4.23 3.70 4.91 8.55 8.80 6.70 5.71 10 13
Short-Term Debt		 0.15 0.15 0.15 0.15 0.07 0.04 0.00 0.00 0.00 0.00
Accounts Payable		 0.73 1.29 1.34 2.53 1.69 2.70 0.62 1.59 0.99 0.95
Accrued Expenses		 1.86 2.51 2.03 2.16 3.51 3.15 3.66 4.12 9.27 12
Other Current Liabilities		 - 0.28 0.18 0.07 3.27 2.91 2.42 0.00 0.00 0.00
Total Noncurrent Liabilities		 0.12 0.06 0.03 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 15 6.78 5.10 -0.53 86 80 73 168 153 189
Total Preferred & Common Equity		 15 6.78 5.10 -0.53 86 80 73 168 153 189
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 15 6.78 5.10 -0.53 86 80 73 168 153 189
Common Stock		 78 78 82 82 194 198 203 327 332 388
Retained Earnings		 -63 -72 -77 -82 -108 -118 -130 -159 -179 -199
Accumulated Other Comprehensive Income / (Loss)		 -0.00 -0.00 -0.00 0.00 -0.00 -0.00 -0.00 -0.03 -0.07 -0.11

Annual Metrics And Ratios for Inhibikase Therapeutics

This table displays calculated financial ratios and metrics derived from Inhibikase Therapeutics' official financial filings.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 25,155,198.00 25,227,051.00 6,174,280.00 - 75,175,306.00
DEI Adjusted Shares Outstanding		 0.00 4,192,533.00 4,204,509.00 6,174,280.00 - 75,175,306.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -3.53 -4.27 -3.10 - -0.64
Growth Metrics		 - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -423.90% -22.73% -9.88% -43.44% -81.51%
EBIT Growth		 0.00% -423.90% -22.77% -10.82% -42.31% -81.56%
NOPAT Growth		 0.00% -423.90% -22.77% -10.82% -42.31% -81.80%
Net Income Growth		 0.00% -419.19% -22.10% -5.40% -44.62% -75.36%
EPS Growth		 0.00% -131.43% -22.10% 26.17% 63.29% 57.76%
Operating Cash Flow Growth		 0.00% -1,165.95% -21.36% -4.23% -5.88% -45.11%
Free Cash Flow Firm Growth		 0.00% 0.00% -12.73% -2.48% -42.27% -69.86%
Invested Capital Growth		 0.00% 39.36% 28.75% -22.27% -26.20% -128.32%
Revenue Q/Q Growth		 0.00% 0.00% -100.00% -100.00% 100.00% 0.00%
EBITDA Q/Q Growth		 0.00% -35.15% 3.78% -0.34% -42.55% -1.67%
EBIT Q/Q Growth		 0.00% -35.15% 3.75% -0.34% -42.49% -1.66%
NOPAT Q/Q Growth		 0.00% -35.15% 3.75% -0.34% -42.49% -1.66%
Net Income Q/Q Growth		 0.00% -35.00% 4.05% 0.53% -40.66% -1.26%
EPS Q/Q Growth		 0.00% -84.09% 4.05% -1.61% 47.27% 7.55%
Operating Cash Flow Q/Q Growth		 0.00% -28.25% 3.02% 0.63% -11.04% -8.47%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 1.73% -1.46% -62.88% 5.45%
Invested Capital Q/Q Growth		 0.00% -62.63% -62.46% -31.76% 29.27% -32.47%
Profitability Metrics		 - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 101.04% 100.13% 99.59% 94.72% 96.26% 92.85%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -7.15% -37.79% -60.74% -118.88% -52.00% -36.05%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -7.15% -37.79% -60.74% -118.88% -52.00% -36.05%
Return on Equity Simple (ROE_SIMPLE)		 -29.11% -38.49% -85.83% -173.34% -29.01% 0.00%
Net Operating Profit after Tax (NOPAT)		 -1.97 -10 -13 -14 -20 -36
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -2.00% -10.54% -16.91% -27.81% -13.60% -8.60%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -125.36% -21.07% -21.04%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -2.82 -15 -18 -20 -29 -52
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -2.82 -15 -18 -20 -29 -52
Valuation Ratios		 - - - - - -
Price to Book Value (P/BV)		 1.42 0.96 0.60 0.71 2.30 0.89
Price to Tangible Book Value (P/TBV)		 1.42 0.96 0.60 0.71 2.30 0.89
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - -
Debt to Equity		 0.01 0.00 0.02 0.02 0.00 0.00
Long-Term Debt to Equity		 0.01 0.00 0.01 0.01 0.00 0.00
Financial Leverage		 -1.10 -1.08 -1.07 -1.12 -1.04 -1.03
Leverage Ratio		 0.37 0.73 1.13 1.23 1.07 1.04
Compound Leverage Factor		 0.37 0.73 1.13 1.17 1.03 0.97
Debt to Total Capital		 0.79% 0.00% 1.64% 2.14% 0.12% 0.00%
Short-Term Debt to Total Capital		 0.11% 0.00% 0.68% 1.34% 0.12% 0.00%
Long-Term Debt to Total Capital		 0.69% 0.00% 0.96% 0.80% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 99.21% 100.00% 98.36% 97.86% 99.88% 100.00%
Debt to EBITDA		 -0.11 0.00 -0.02 -0.01 0.00 0.00
Net Debt to EBITDA		 4.84 0.00 1.25 0.65 3.41 0.00
Long-Term Debt to EBITDA		 -0.10 0.00 -0.01 0.00 0.00 0.00
Debt to NOPAT		 -0.16 0.00 -0.03 -0.02 -0.01 0.00
Net Debt to NOPAT		 6.91 0.00 1.79 0.93 4.87 0.00
Long-Term Debt to NOPAT		 -0.14 0.00 -0.02 -0.01 0.00 0.00
Altman Z-Score		 8.39 4.43 -2.15 -8.80 33.95 10.23
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - -
Current Ratio		 3.13 10.47 6.59 4.13 26.37 21.70
Quick Ratio		 2.96 10.08 6.25 3.85 26.13 21.54
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -12 -13 -14 -19 -33
Operating Cash Flow to CapEx		 0.00% 0.00% -7,132.89% -127,019.55% 0.00% -207,377.15%
Free Cash Flow to Firm to Interest Expense		 0.00 -594.88 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -38.41 -717.62 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -38.41 -717.62 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - -
Invested Capital		 -3.85 -2.33 -1.66 -2.03 -2.57 -5.86
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 1.52 0.67 -0.37 -0.53 -3.29
Enterprise Value (EV)		 43 -3.77 -10 -5.17 121 -25
Market Capitalization		 56 37 13 7.84 218 154
Book Value per Share		 $4.85 $1.53 $0.83 $1.78 $1.41 $2.30
Tangible Book Value per Share		 $4.85 $1.53 $0.83 $1.78 $1.41 $2.30
Total Capital		 40 38 21 11 95 173
Total Debt		 0.32 0.00 0.35 0.24 0.11 0.00
Total Long-Term Debt		 0.28 0.00 0.21 0.09 0.00 0.00
Net Debt		 -14 -41 -23 -13 -97 -179
Capital Expenditures (CapEx)		 0.00 0.00 0.24 0.01 0.00 0.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -3.85 -2.33 -2.23 -2.33 -2.72 -6.96
Debt-free Net Working Capital (DFNWC)		 10 38 21 11 95 172
Net Working Capital (NWC)		 10 38 21 11 95 172
Net Nonoperating Expense (NNE)		 0.87 4.45 5.36 4.97 7.51 12
Net Nonoperating Obligations (NNO)		 -44 -41 -23 -13 -97 -179
Total Depreciation and Amortization (D&A)		 0.00 0.00 0.01 0.18 0.03 0.06
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($4.86) ($4.32) ($3.57) ($1.16) ($0.49)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 4.20M 4.20M 5.33M 23.71M 98.31M
Adjusted Diluted Earnings per Share		 $0.00 ($4.86) ($4.32) ($3.57) ($1.16) ($0.49)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 4.20M 4.20M 5.33M 23.71M 98.31M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($4.86) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 3.03M 4.83M 6.48M 74.34M 132.03M
Normalized Net Operating Profit after Tax (NOPAT)		 -1.97 -10 -13 -14 -20 -36
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - -
EBIT to Interest Expense		 -95.86 -741.16 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 -67.10 -518.81 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -95.86 -741.16 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -67.10 -518.81 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Inhibikase Therapeutics

This table displays calculated financial ratios and metrics derived from Inhibikase Therapeutics' official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding		 6,476,844.00 6,476,844.00 7,464,070.00 - 74,341,540.00 74,341,540.00 74,516,635.00 75,175,306.00 132,032,636.00 132,032,636.00 139,535,900.00
DEI Adjusted Shares Outstanding		 6,476,844.00 6,476,844.00 7,464,070.00 - 74,341,540.00 74,341,540.00 74,516,635.00 75,175,306.00 132,032,636.00 132,032,636.00 139,535,900.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.72 -0.77 -0.77 - -0.18 -0.13 -0.16 -0.17 -0.12 -0.15 -0.15
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% -100.00% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -1.46% 18.79% -22.27% -193.89% -205.23% -114.28% -118.95% -6.60% -22.33% -94.73% -74.42%
EBIT Growth		 -1.49% 20.71% -22.24% -193.60% -205.08% -114.48% -119.11% -6.55% -22.22% -94.30% -74.09%
NOPAT Growth		 -1.43% 18.57% -22.20% -193.60% -205.25% -114.48% -119.11% -6.55% -22.22% -94.34% -74.09%
Net Income Growth		 -3.84% 14.16% -25.74% -190.40% -194.19% -99.93% -106.48% -4.96% -19.75% -97.58% -71.56%
EPS Growth		 25.51% 29.79% 13.33% 26.09% 79.45% 83.33% 80.00% 80.39% 33.33% 0.00% 23.08%
Operating Cash Flow Growth		 35.25% -10.71% -18.90% -55.28% -6.12% -10.29% -117.02% -40.60% -193.89% -123.23% -63.81%
Free Cash Flow Firm Growth		 88.74% 65.26% 29.26% -214.05% -753.98% -30.92% -308.40% 25.45% -205.26% -521.53% -89.84%
Invested Capital Growth		 -3,730.67% -127.30% -135.10% -26.20% -166.89% -184.15% -21.90% -128.32% 62.73% 24.87% -2.30%
Revenue Q/Q Growth		 100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -8.68% -5.56% -15.40% -122.00% -12.87% 25.71% -17.92% -8.09% -29.52% -17.99% -5.60%
EBIT Q/Q Growth		 -8.66% -5.55% -15.38% -121.86% -12.91% 25.61% -17.87% -7.89% -29.52% -17.99% -5.60%
NOPAT Q/Q Growth		 -8.60% -5.61% -15.38% -121.86% -12.91% 25.80% -17.87% -7.89% -29.52% -17.99% -5.60%
Net Income Q/Q Growth		 -11.29% -6.67% -16.50% -109.98% -12.74% 27.51% -20.32% -6.74% -28.63% -19.60% -4.47%
EPS Q/Q Growth		 -5.80% 9.59% 1.52% 21.54% 70.59% 26.67% -18.18% 23.08% 0.00% -10.00% 9.09%
Operating Cash Flow Q/Q Growth		 -12.33% -30.70% 3.43% -9.52% 23.24% -35.84% -90.03% 29.05% -60.45% -3.18% -39.45%
Free Cash Flow Firm Q/Q Growth		 75.79% -211.09% 2.38% -327.18% 34.17% 52.31% -204.53% 22.03% -169.57% 2.90% 6.99%
Invested Capital Q/Q Growth		 -35.86% 3.54% -36.15% 29.27% -187.32% -2.70% 41.59% -32.47% 53.10% -107.03% 20.46%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 99.94% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 99.72% 100.00% 100.00% 100.00%
Interest Burden Percent		 97.23% 98.20% 99.15% 93.84% 93.70% 91.54% 93.44% 92.71% 91.81% 93.07% 92.07%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -119.64% -149.69% -270.10% -52.00% -79.02% -97.49% -131.71% -36.05% -40.23% -51.96% -52.87%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -119.64% -149.69% -270.10% -52.00% -79.02% -97.49% -131.71% -36.05% -40.23% -51.96% -52.87%
Return on Equity Simple (ROE_SIMPLE)		 -283.34% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -3.35 -3.54 -4.08 -9.05 -10 -7.58 -8.94 -9.64 -12 -15 -16
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -7.45% -10.03% -17.28% -5.58% -6.74% -4.89% -7.44% -2.24% -2.95% -3.94% -3.63%
Return On Investment Capital (ROIC_SIMPLE)		 -47.92% -67.03% 1,058.49% -9.53% -11.91% -9.47% -12.26% -5.58% -7.45% -9.61% -8.24%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -4.79 -5.05 -5.83 -13 -15 -11 -13 -14 -18 -21 -22
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -4.78 -5.04 -5.82 -13 -15 -11 -13 -14 -18 -21 -22
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.06 1.54 0.00 2.30 1.90 1.81 1.66 0.89 1.32 1.75 1.52
Price to Tangible Book Value (P/TBV)		 2.06 1.54 0.00 2.30 1.90 1.81 1.66 0.89 1.32 1.75 1.52
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.03 0.03 -0.27 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.09 -1.16 -1.36 -1.04 -1.11 -1.12 -1.11 -1.03 -1.04 -1.06 -1.03
Leverage Ratio		 1.22 1.27 1.54 1.07 1.14 1.15 1.16 1.04 1.06 1.08 1.08
Compound Leverage Factor		 1.19 1.25 1.52 1.00 1.07 1.05 1.08 0.97 0.97 1.01 0.99
Debt to Total Capital		 3.00% 3.37% -37.68% 0.12% 0.09% 0.05% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 2.16% 2.89% -37.68% 0.12% 0.09% 0.05% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.83% 0.49% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 97.00% 96.63% 137.68% 99.88% 99.91% 99.95% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 -0.01 -0.01 -0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.48 0.41 0.15 3.41 2.43 1.99 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.01 -0.01 -0.01 -0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.68 0.58 0.22 4.87 3.46 2.83 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -7.81 -12.11 -29.77 34.47 10.40 8.70 9.08 10.92 22.83 14.84 12.64
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 2.55 2.32 0.85 26.37 11.01 10.09 11.73 21.70 30.14 15.82 15.34
Quick Ratio		 2.30 2.14 0.66 26.13 10.90 9.96 11.55 21.54 29.83 15.50 14.92
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -0.66 -2.04 -1.99 -8.52 -5.61 -2.67 -8.14 -6.35 -17 -17 -15
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% -30,625.64% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -2.76 -2.67 -3.63 -2.57 -7.37 -7.57 -4.42 -5.86 -2.75 -5.69 -4.53
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -2.69 -1.49 -2.09 -0.53 -4.61 -4.91 -0.79 -3.29 4.63 1.88 -0.10
Enterprise Value (EV)		 4.45 0.07 6.60 121 70 57 43 -25 51 109 93
Market Capitalization		 14 7.84 9.70 218 163 145 121 154 222 268 287
Book Value per Share		 $1.05 $0.79 ($0.07) $1.41 $1.15 $1.08 $0.98 $2.30 $1.27 $1.16 $1.35
Tangible Book Value per Share		 $1.05 $0.79 ($0.07) $1.41 $1.15 $1.08 $0.98 $2.30 $1.27 $1.16 $1.35
Total Capital		 6.99 5.27 -0.39 95 86 80 73 173 168 153 189
Total Debt		 0.21 0.18 0.15 0.11 0.07 0.04 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.06 0.03 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -9.54 -7.76 -3.10 -97 -93 -88 -77 -179 -170 -159 -193
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -3.02 -2.89 -3.82 -2.72 -7.49 -7.63 -5.48 -6.96 -3.90 -6.93 -7.55
Debt-free Net Working Capital (DFNWC)		 6.73 5.05 -0.57 95 86 80 72 172 166 152 186
Net Working Capital (NWC)		 6.57 4.90 -0.72 95 86 80 72 172 166 152 186
Net Nonoperating Expense (NNE)		 1.30 1.42 1.70 3.08 3.46 2.33 2.99 3.09 3.89 4.86 4.91
Net Nonoperating Obligations (NNO)		 -9.54 -7.76 -3.10 -97 -93 -88 -77 -179 -170 -159 -193
Total Depreciation and Amortization (D&A)		 0.01 0.01 0.01 0.01 0.01 0.02 0.02 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.73) ($0.66) ($0.65) ($0.51) ($0.15) ($0.11) ($0.13) ($0.10) ($0.10) ($0.11) ($0.10)
Adjusted Weighted Average Basic Shares Outstanding		 6.34M 7.54M 8.88M 23.71M 89.54M 90.01M 90.05M 98.31M 172.31M 174.57M 196.94M
Adjusted Diluted Earnings per Share		 ($0.73) ($0.66) ($0.65) ($0.51) ($0.15) ($0.11) ($0.13) ($0.10) ($0.10) ($0.11) ($0.10)
Adjusted Weighted Average Diluted Shares Outstanding		 6.34M 7.54M 8.88M 23.71M 89.54M 90.01M 90.05M 98.31M 172.31M 174.57M 196.94M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($0.51) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 6.48M 7.46M 67.19M 74.34M 74.34M 74.52M 75.18M 132.03M 132.03M 139.54M 140.27M
Normalized Net Operating Profit after Tax (NOPAT)		 -3.35 -3.54 -4.08 -9.05 -10 -7.58 -8.94 -9.64 -12 -15 -16
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Inhibikase Therapeutics (NASDAQ: IKT) remains a development-stage biotechnology company with no meaningful product revenue. Revenue was $0 in each reported quarter from Q2 2024 through Q2 2026, while operating expenses increased as the company invested in research and development. The latest quarter included a net loss attributable to common shareholders of $19.6 million, or $0.11 per share, compared with a $16.4 million loss in Q1 2026 and a $9.9 million loss in Q2 2025.

The main driver of the larger Q2 loss was rising research and development spending. R&D expense increased to $13.4 million in Q2 2026 from $10.8 million in Q1 and $5.3 million in Q2 2025. Selling, general and administrative expense also rose modestly to $7.7 million. Total operating expenses reached $21.1 million, up from $17.8 million in Q1 2026 and $10.8 million in Q2 2025.

Liquidity is currently much stronger than it was in 2024. At June 30, 2026, IKT held $31.2 million in cash and $127.8 million in short-term investments, for approximately $159.9 million in cash and investments. This compares with roughly $77.3 million at September 30, 2025 and just $3.2 million at September 30, 2024. However, operating cash burn remains substantial: the company used $12.4 million in operating cash in Q2 2026 after using $12.1 million in Q1.

The balance sheet carries little debt. Total liabilities were $10.3 million at the end of Q2 2026, with no short-term or noncurrent debt reported, against $153.3 million of shareholders’ equity. Nevertheless, accumulated retained losses reached $178.7 million, underscoring the company’s long history of losses and dependence on external capital until a product or partnership generates revenue.

  • Significant liquidity cushion: Cash and short-term investments totaled approximately $159.9 million at June 30, 2026, providing funding for ongoing clinical and corporate activities.
  • Low leverage: IKT reported no short-term debt or noncurrent debt, limiting interest-rate and refinancing pressure on the balance sheet.
  • Strong current position: Current assets of $162.3 million substantially exceeded current liabilities of $10.3 million, indicating considerable short-term balance-sheet flexibility.
  • R&D investment is accelerating: R&D expense rose to $13.4 million in Q2 2026, which could support clinical progress and future value creation if the company’s programs succeed.
  • Liquidity improved materially from 2024: The company moved from only a few million dollars of cash and investments in late 2024 to nearly $160 million by mid-2026, largely following equity financing activity.
  • Investment portfolio activity is significant: IKT purchased $55.0 million and sold or received maturities of $49.1 million of investments in Q2 2026. These transactions appear primarily to manage liquidity rather than represent operating growth.
  • Potential runway remains substantial but uncertain: Based on Q2 operating cash usage, the current cash-and-investment balance could cover multiple years of spending, but the runway will shorten if R&D costs rise or clinical programs expand.
  • No commercial revenue: Revenue was $0 in Q2 2026 and in the other recent 2024–2026 quarters provided, leaving IKT dependent on financing, investment income and potential future partnerships.
  • Losses and operating burn are worsening: The Q2 2026 net loss of $19.6 million was higher than the losses reported in Q1 2026 and Q2 2025, while operating cash burn remained above $12 million per quarter.
  • Heavy dilution risk: Weighted-average basic shares increased from 6.3 million in Q1 2024 to 174.6 million in Q2 2026. The company raised approximately $107.6 million through common equity issuance in Q4 2025 and another $2.9 million in Q1 2026, demonstrating that future financing could continue to dilute existing shareholders.

Overall, IKT’s financial position has improved substantially because of equity financing and accumulated investments, but its fundamental operating profile remains high risk. Investors should focus on clinical and regulatory milestones, the pace of R&D spending, quarterly cash burn and the company’s ability to raise capital without continued heavy dilution.

11/15/26 04:32 AM ETAI Generated. May Contain Errors.

Inhibikase Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Inhibikase Therapeutics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Inhibikase Therapeutics' net income appears to be on a downward trend, with a most recent value of -$48.26 million in 2025, falling from -$2.85 million in 2020. The previous period was -$27.52 million in 2024. View Inhibikase Therapeutics' forecast to see where analysts expect Inhibikase Therapeutics to go next.

Inhibikase Therapeutics' total operating income in 2025 was -$51.97 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $51.97 million

Over the last 5 years, Inhibikase Therapeutics' total revenue changed from $0.00 in 2020 to $0.00 in 2025, a change of 0.0%.

In the past 12 quarters, Inhibikase Therapeutics' cash and equivalents has ranged from $913.42 thousand in Q3 2024 to $77.74 million in Q2 2025, and is currently $51.70 million as of their latest financial filing in Q3 2026.

Inhibikase Therapeutics had total debt of $0.00 at the end of 2025, a 100.0% decrease from 2024, and a 100.0% decrease since 2020.

Over the last 5 years, Inhibikase Therapeutics' book value per share changed from 4.85 in 2020 to 2.30 in 2025, a change of -52.6%.


Related Companies

Financial statements for NASDAQ:IKT last updated on 11/10/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...
Base Camp Trading | Sponsoredtc pixel
Today's free pick (on me)
Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...
Behind the Markets | Sponsoredtc pixel
Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...
Weiss Ratings | Sponsoredtc pixel
Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
The investigation Porter spent tens of thousands to document
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...
Porter & Company | Sponsoredtc pixel
SHOCKING! Prediction caught on camera
Newly released footage shows James Altucher pulling a document out of a briefcase on camera. It is a document ...
Paradigm Press | Sponsoredtc pixel
Trump’s EO to send this $5 stock ripping higher…?
President Trump's December executive order declared space a national security and economic priority, fueling a...
Traders Agency | Sponsoredtc pixel
Uranium Mine Flood That Sparked a 2006 Price Surge Returns
In 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...
Digest Publishing | Sponsoredtc pixel